Sangamo Therapeutics, Inc (SGMOQ): Cash & Equivalents
$20.95M
As of 2025-12-31
$27.59M
As of 2026-03-31
-40.7%
3-year compound annual growth
-30.7%
5-year compound annual growth
-11.3%
10-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $20.95M | -50.0% | 2026-03-30, Balance as of period end |
| 2024-12-31 | $41.92M | -7.3% | 2026-03-30, Balance as of period end |
| 2023-12-31 | $45.20M | -55.0% | 2025-03-17, Balance as of period end |
| 2022-12-31 | $100.44M | -43.8% | 2024-03-13, Balance as of period end |
| 2021-12-31 | $178.87M | +36.2% | 2023-02-23, Balance as of period end |
| 2020-12-31 | $131.33M | +63.3% | 2022-02-24, Balance as of period end |
| 2019-12-31 | $80.43M | -42.7% | 2021-02-24, Balance as of period end |
| 2018-12-31 | $140.42M | +181.8% | 2020-02-28, Balance as of period end |
| 2017-12-31 | $49.83M | +125.9% | 2019-03-01, Balance as of period end |
| 2016-12-31 | $22.06M | -68.2% | 2018-03-01, Balance as of period end |
| 2015-12-31 | $69.48M | n/m | 2018-03-01, Balance as of period end |
| 2014-12-31 | $6.03M | -40.8% | 2017-02-28, Balance as of period end |
| 2013-12-31 | $10.19M | -53.0% | 2016-02-18, Balance as of period end |
| 2012-12-31 | $21.68M | +29.3% | 2015-02-25, Balance as of period end |
| 2011-12-31 | $16.77M | +55.5% | 2014-02-24, Balance as of period end |
| 2010-12-31 | $10.78M | -49.0% | 2013-02-26, Balance as of period end |
| 2009-12-31 | $21.16M | n/a | 2012-02-23, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Sangamo Therapeutics, Inc (SGMOQ) | 2025-12-31 | $20.95M | -50.0% |
| Kymera Therapeutics, Inc. (KYMR) | 2025-12-31 | $357.01M | +196.9% |
| Voyager Therapeutics, Inc. (VYGR) | 2025-12-31 | $65.30M | -8.5% |
| Editas Medicine, Inc. (EDIT) | 2025-12-31 | $146.65M | +11.5% |
| C4 Therapeutics, Inc. (CCCC) | 2025-12-31 | $74.60M | +34.4% |
| X4 Pharmaceuticals, Inc (XFOR) | 2025-12-31 | $217.05M | +289.7% |
| Fennec Pharmaceuticals Inc. (FENC) | 2025-12-31 | $36.79M | +38.1% |
| Precision Biosciences Inc (DTIL) | 2025-12-31 | $110.82M | +29.0% |
| Scilex Holding Co (SCLX) | 2025-12-31 | $4.96M | +51.4% |
Compare SGMOQ, KYMR, VYGR, EDIT side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗